$XBI $129.36 -3%
Want to access our searchable database of over 900 catalyst events and more? Try BiopharmIQ for 30 days free, no credit card required. Check it out here!
Covid Updates
$VIR -6% Ph 2 data combo w/ $GSK $LLY. source
$GRTS +1% 1st patient dosed in ph 1 study. source
$HGEN +60% Ph 3 data, Lenzilumab improves survival without ventilation in hospitalized covid-19 patients. source
$CYDY +4% Philippines approval of Leronlimab for covid-19. source
Pipeline Updates
$WVE -18% Ph 1b/2a results do not support further development. source
$MIRM +4% NDA acceptance & priority review for maralixibat, PDUFA date 9/29/21. source
$TGTX -5% Complete rolling BLA for ubli + umbra in CLL. source
$QURE +4% Update on findings from HCC case in hemo b program. source
$CERC -7% WW license agreement with Kyowa for CERC-002. source
$AVEO -6% FOTIVDA added to clinical practice guidelines. source
$AMPH +0% FDA approval for dextrose injections. source
$BLUE +3% FDA approval of ide-cel for multiple myeloma. source
Finance Updates
$AMTI -2% Offering. source
$HGEN +60% Offering. source
Comments